Cargando…

The PPARα agonist fenofibrate attenuates disruption of dopamine function in a maternal immune activation rat model of schizophrenia

AIMS: Prenatal maternal immune activation (MIA) is associated with a risk to develop schizophrenia and affects dopamine systems in the ventral tegmental area (VTA), key region in the neurobiology of psychoses. Considering the well‐described sex differences in schizophrenia, we investigated whether s...

Descripción completa

Detalles Bibliográficos
Autores principales:	De Felice, Marta, Melis, Miriam, Aroni, Sonia, Muntoni, Anna Lisa, Fanni, Silvia, Frau, Roberto, Devoto, Paola, Pistis, Marco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6488881/ https://www.ncbi.nlm.nih.gov/pubmed/30461214 http://dx.doi.org/10.1111/cns.13087

Ejemplares similares

Maternal Immune Activation Disrupts Dopamine System in the Offspring
por: Luchicchi, Antonio, et al.
Publicado: (2016)

Profound Modification of Fatty Acid Profile and Endocannabinoid-Related Mediators in PPARα Agonist Fenofibrate-Treated Mice
por: Murru, Elisabetta, et al.
Publicado: (2022)

PPAR-Alpha Agonists as Novel Antiepileptic Drugs: Preclinical Findings
por: Puligheddu, Monica, et al.
Publicado: (2013)

The PPARα Agonist Fenofibrate Reduces Prepulse Inhibition Disruption in a Neurodevelopmental Model of Schizophrenia
por: Rolland, Benjamin, et al.
Publicado: (2012)

Transgenerational Sex-dependent Disruption of Dopamine Function Induced by Maternal Immune Activation
por: Santoni, Michele, et al.
Publicado: (2022)

Δ(9)-Tetrahydrocannabinol During Adolescence Attenuates Disruption of Dopamine Function Induced in Rats by Maternal Immune Activation
por: Lecca, Salvatore, et al.
Publicado: (2019)

Combined α(2)- and D(2)-receptor blockade activates noradrenergic and dopaminergic neurons, but extracellular dopamine in the prefrontal cortex is determined by uptake and release from noradrenergic terminals
por: Sagheddu, Claudia, et al.
Publicado: (2023)

Repurposing Peroxisome Proliferator-Activated Receptor Agonists in Neurological and Psychiatric Disorders
por: Sagheddu, Claudia, et al.
Publicado: (2021)

Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)α agonist fenofibrate and the PPARγ agonist pioglitazone
por: Syversen, Unni, et al.
Publicado: (2009)

In vitro and in vivo effects of the PPAR-alpha agonists fenofibrate and retinoic acid in endometrial cancer
por: Saidi, Samir A, et al.
Publicado: (2006)

The whole transcriptome effects of the PPARα agonist fenofibrate on livers of hepatocyte humanized mice
por: de la Rosa Rodriguez, Montserrat A., et al.
Publicado: (2018)

PPAR-Alpha Agonist Fenofibrate Combined with Octreotide Acetate in the Treatment of Acute Hyperlipidemia Pancreatitis
por: Bao, Wen, et al.
Publicado: (2021)

HMGB1 Is Involved in the Protective Effect of the PPARα Agonist Fenofibrate against Cardiac Hypertrophy
por: Jia, Zhankui, et al.
Publicado: (2014)

PPAR-α Agonist Fenofibrate Decreased RANTES Levels in Type 2 Diabetes Patients with Hypertriglyceridemia
por: Feng, Xiaomeng, et al.
Publicado: (2016)

The PPARα agonist fenofibrate suppresses B-cell lymphoma in mice by modulating lipid metabolism()()
por: Huang, Jianfeng, et al.
Publicado: (2013)

Sex-specific tonic 2-arachidonoylglycerol signaling at inhibitory inputs onto dopamine neurons of Lister Hooded rats
por: Melis, Miriam, et al.
Publicado: (2013)

Prenatal THC exposure produces a hyperdopaminergic phenotype rescued by pregnenolone
por: Frau, Roberto, et al.
Publicado: (2019)

Endocannabinoids and the Processing of Value-Related Signals
por: Melis, Miriam, et al.
Publicado: (2012)

PPAR-α Agonist Fenofibrate Decreased Serum Irisin Levels in Type 2 Diabetes Patients with Hypertriglyceridemia
por: Feng, Xiaomeng, et al.
Publicado: (2015)

PPARα agonist fenofibrate prevents postoperative cognitive dysfunction by enhancing fatty acid oxidation in mice
por: Liu, Tiantian, et al.
Publicado: (2023)

The peroxisome proliferator-activated receptor (PPAR) alpha agonist fenofibrate maintains bone mass, while the PPAR gamma agonist pioglitazone exaggerates bone loss, in ovariectomized rats
por: Stunes, Astrid K, et al.
Publicado: (2011)

Endocannabinoid Signaling in Midbrain Dopamine Neurons: More than Physiology?
por: Melis, M, et al.
Publicado: (2007)

PPARα Agonist Fenofibrate Reduced the Secreting Load of β-Cells in Hypertriglyceridemia Patients with Normal Glucose Tolerance
por: Liu, Jia, et al.
Publicado: (2016)

PPAR-α Agonist Fenofibrate Suppressed the Formation of Ocular Surface Squamous Metaplasia Induced by Topical Benzalkonium Chloride
por: He, Huan, et al.
Publicado: (2020)

Activation of PPARα by Fenofibrate Attenuates the Effect of Local Heart High Dose Irradiation on the Mouse Cardiac Proteome
por: Azimzadeh, Omid, et al.
Publicado: (2021)

PPAR-α Agonist Fenofibrate Reduces Insulin Resistance in Impaired Glucose Tolerance Patients with Hypertriglyceridemia: A Cross-Sectional Study
por: Feng, Xiaomeng, et al.
Publicado: (2017)

Selective inhibition of dopamine‐beta‐hydroxylase enhances dopamine release from noradrenergic terminals in the medial prefrontal cortex
por: Devoto, Paola, et al.
Publicado: (2015)

Effects and mechanisms of PPARα activator fenofibrate on myocardial remodelling in hypertension
por: Li, Chuan-Bao, et al.
Publicado: (2009)

L-carnitine and PPARα-agonist fenofibrate are involved in the regulation of Carnitine Acetyltransferase (CrAT) mRNA levels in murine liver cells
por: Kienesberger, Klemens, et al.
Publicado: (2014)

The PPARα Agonist Fenofibrate Prevents Formation of Protein Aggregates (Mallory-Denk bodies) in a Murine Model of Steatohepatitis-like Hepatotoxicity
por: Nikam, Aniket, et al.
Publicado: (2018)

Noradrenergic Source of Dopamine Assessed by Microdialysis in the Medial Prefrontal Cortex
por: Devoto, Paola, et al.
Publicado: (2020)

Conjugated Linoleic Acid and Brain Metabolism: A Possible Anti-Neuroinflammatory Role Mediated by PPARα Activation
por: Murru, Elisabetta, et al.
Publicado: (2021)

Direct Effects of PPARα Agonists on Retinal Inflammation and Angiogenesis May Explain How Fenofibrate Lowers Risk of Severe Proliferative Diabetic Retinopathy
por: Abcouwer, Steven F.
Publicado: (2013)

Fenofibrate: direct attenuating effects on tumor growth
por: Kapoor, Shailendra
Publicado: (2013)

The Peroxisome Proliferator-Activated Receptor (PPAR) α Agonist Fenofibrate Suppresses Chemically Induced Lung Alveolar Proliferative Lesions in Male Obese Hyperlipidemic Mice
por: Kuno, Toshiya, et al.
Publicado: (2014)

PPAR-α Agonist Fenofibrate Prevented Diabetic Nephropathy by Inhibiting M1 Macrophages via Improving Endothelial Cell Function in db/db Mice
por: Feng, Xiaomeng, et al.
Publicado: (2021)

PPAR-α Agonist Fenofibrate Ameliorates Sjögren Syndrome–Like Dacryoadenitis by Modulating Th1/Th17 and Treg Cell Responses in NOD Mice
por: Guo, Xingyi, et al.
Publicado: (2022)

Ciglitazone—a human PPARγ agonist—disrupts dorsoventral patterning in zebrafish
por: Cheng, Vanessa, et al.
Publicado: (2019)

The Atypical Dopamine Transporter Inhibitor CE-158 Enhances Dopamine Neurotransmission in the Prefrontal Cortex of Male Rats: A Behavioral, Electrophysiological, and Microdialysis Study
por: Sagheddu, Claudia, et al.
Publicado: (2023)

Disrupted Sleep and Circadian Rhythms in Schizophrenia and Their Interaction With Dopamine Signaling
por: Ashton, Anna, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_817d4ve5r6pton3bm2m9g699fn